Dissolve-E: AWMF Guideline Registry
0.2.0 - ci-build

Dissolve-E: AWMF Guideline Registry - Local Development build (v0.2.0) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions

Table of Contents

.. 0 Table of Contents
... 1 DISSOLVE-E Implementation Guide
... 2 Profiles
... 3 Extensions
... 4 Code Systems
... 5 Value Sets
... 6 Downloads
... 7 Examples
... 8 Artifacts Summary
.... 8.1 AWMF Member Organization
.... 8.2 AWMF S1 Guideline Registry Record
.... 8.3 AWMF S2e Guideline Registry Record
.... 8.4 AWMF S2k Guideline Registry Record
.... 8.5 AWMF S3 Guideline Registry Record
.... 8.6 Citation List
.... 8.7 Conceptual Cohort Definition Comparator
.... 8.8 Conceptual Cohort Definition Intervention
.... 8.9 Conceptual Cohort Definition Outcome
.... 8.10 Conceptual Cohort Definition Population
.... 8.11 Evidence Assessment
.... 8.12 Evidence Internal Assessment AGREE II
.... 8.13 Evidence Internal Assessment AMSTAR 2
.... 8.14 Evidence Internal Assessment Cochrane Risk of Bias
.... 8.15 Evidence Internal Assessment ROBIS
.... 8.16 Evidence Internal Validity Assessment
.... 8.17 Evidence Overall Assessment GRADE
.... 8.18 Evidence Overall Assessment Oxford 2011
.... 8.19 Evidence Overall Quality Assessment
.... 8.20 Evidence Report with Contact Slices
.... 8.21 Guideline
.... 8.22 Guideline Attachment
.... 8.23 Guideline Author
.... 8.24 Guideline Author Role
.... 8.25 Guideline Registry Record
.... 8.26 Medical Society
.... 8.27 Outcome Evidence
.... 8.28 Patient Organization
.... 8.29 PICO Question
.... 8.30 Recommendation
.... 8.31 Recommendation Justification
.... 8.32 Recommendation Justification AWMF
.... 8.33 Recommendation Justification Expert Consensus
.... 8.34 Recommendation Justification GRADE
.... 8.35 Recommendation Justification OXFORD 2009
.... 8.36 Recommendation Justification OXFORD 2011
.... 8.37 Recommendation Justification SIGN
.... 8.38 Artifact Contact (Extended)
.... 8.39 Author Language
.... 8.40 Composition Approval Date
.... 8.41 Composition Effective Period
.... 8.42 Composition Last Review Date
.... 8.43 Consultation Period
.... 8.44 First Publication Date
.... 8.45 Guideline Author Role
.... 8.46 Medical Subject
.... 8.47 Medical Subject Category
.... 8.48 Planned Completion Date
.... 8.49 Publication Date
.... 8.50 Recommendation Review Status
.... 8.51 Registration Date
.... 8.52 RelatesTo Classifier
.... 8.53 RelatesTo Label
.... 8.54 Section Coding
.... 8.55 Section Intended Audience
.... 8.56 Section Keyword
.... 8.57 Section Language
.... 8.58 Submission Date
.... 8.59 AGREE II Domains Value Set
.... 8.60 AMSTAR 2 Confidence Ratings Value Set
.... 8.61 AWMF Guideline Class
.... 8.62 AWMF Guideline Status
.... 8.63 Body System Conditions
.... 8.64 Care Level
.... 8.65 Care Stage
.... 8.66 Clinical Application Type
.... 8.67 Content Types
.... 8.68 Dissemination Website
.... 8.69 Encounter Type
.... 8.70 Guideline Author Role
.... 8.71 Guideline Contact Point VS
.... 8.72 Guideline Release Type
.... 8.73 Guideline Sections
.... 8.74 Intended Audience Value Set
.... 8.75 Level Of Consensus
.... 8.76 Medical Subject Categories
.... 8.77 OCEBM 2009 Levels of Evidence Value Set
.... 8.78 OCEBM 2011 Levels of Evidence Value Set
.... 8.79 PICO related terms
.... 8.80 Rating Acceptability
.... 8.81 Rating Benefits And Harms
.... 8.82 Rating Certainty Of Evidence
.... 8.83 Rating Concern Degree
.... 8.84 Rating Equity
.... 8.85 Rating Feasibility
.... 8.86 Rating Preference And Values
.... 8.87 Rating Resources
.... 8.88 Recommendation Direction
.... 8.89 Recommendation Review Status Value Set
.... 8.90 Recommendation Strength (AWMF) ValueSet
.... 8.91 Recommendation Synthesis Type
.... 8.92 Recommendation Tags
.... 8.93 Remark Type
.... 8.94 RoB2 Overall Judgment ValueSet
.... 8.95 ROBIS Judgment of Risk of Bias Value Set
.... 8.96 ROBIS Risk of Bias Domains Value Set
.... 8.97 SIGN Grade of Recommendation Value Set
.... 8.98 SIGN Level of Evidence Value Set
.... 8.99 Target Patient Group
.... 8.100 AGREE II Domains
.... 8.101 AMSTAR 2 Overall Confidence Ratings
.... 8.102 awmf
.... 8.103 AWMF Guideline Class
.... 8.104 AWMF Guideline Status
.... 8.105 Body System Conditions
.... 8.106 Care Setting
.... 8.107 Clinical Application Type
.... 8.108 Contact Point
.... 8.109 Evidence To Decision Certainty Rating
.... 8.110 Evidence To Decision Certainty type
.... 8.111 Guideline Author Role
.... 8.112 Guideline Release Type
.... 8.113 Guideline Sections
.... 8.114 Intended Audience Code System
.... 8.115 Level of Consensus
.... 8.116 Medical Subject Categories
.... 8.117 OCEBM 2009 Levels of Evidence
.... 8.118 OCEBM 2011 Levels of Evidence
.... 8.119 PICO Related Terms
.... 8.120 Recommendation Direction
.... 8.121 Recommendation Review Status Code System
.... 8.122 Recommendation Strength (AWMF)
.... 8.123 Recommendation Synthesis Type
.... 8.124 Recommendation Tags
.... 8.125 Related Artifact Types
.... 8.126 Remark Type
.... 8.127 RoB2 Overall Judgment
.... 8.128 ROBIS Judgment of Risk of Bias
.... 8.129 ROBIS Risk of Bias Domains
.... 8.130 SIGN Grade of Recommendation
.... 8.131 SIGN Level of Evidence
.... 8.132 Target Patient Group
.... 8.133 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)
.... 8.134 AWMF Guideline Record S3 Example
.... 8.135 AWMF Guideline S1 Example
.... 8.136 AWMF Guideline S2e Example
.... 8.137 AWMF Guideline S2k Example
.... 8.138 AWMF Member Organization Example
.... 8.139 Certainty of Evidence Rating for Multiplex-PCR-Diagnostik - Antibiotic Days
.... 8.140 Certainty of Evidence Rating for Multiplex-PCR-Diagnostik - Mortality
.... 8.141 Certainty of Evidence Rating for Multiplex-PCR-Diagnostik - Time to Deescalation
.... 8.142 Certainty of Evidence Rating Ris of Bias for Cognitive Tests When Suspecting Dementia - Sensitivity
.... 8.143 Certainty of Evidence Rating Ris of Bias for Cognitive Tests When Suspecting Dementia - Specificity
.... 8.144 Citation Systematic Review
.... 8.145 Concept map from concepts from standardized vocabularies (that are not standard OMOP concepts) to Concept IDs of OMOP standard Concepts
.... 8.146 contributor0
.... 8.147 contributor1
.... 8.148 contributor2
.... 8.149 contributor3
.... 8.150 contributor4
.... 8.151 DEGRO
.... 8.152 DEGUM
.... 8.153 DGA
.... 8.154 DGAI
.... 8.155 DGCH
.... 8.156 DGE-BV
.... 8.157 DGG
.... 8.158 DGGG
.... 8.159 DGHM
.... 8.160 DGHO
.... 8.161 DGI
.... 8.162 DGIIN
.... 8.163 DGIM
.... 8.164 DGN
.... 8.165 DGP
.... 8.166 DGP (Palliativmedizin)
.... 8.167 DGP (Pathologie)
.... 8.168 DGPPN
.... 8.169 DGU
.... 8.170 Dirk Hellwig
.... 8.171 Dirk Hellwig for DGN in the context of 018-038
.... 8.172 DRG
.... 8.173 DSG
.... 8.174 EbM-Netzwerk
.... 8.175 Evidence Assessment: Knochenmarkbiopsie - Ereignisfreies Überleben
.... 8.176 Evidence Assessment: Knochenmarkbiopsie - Gesamtüberleben
.... 8.177 Evidence Assessment: Knochenmarkbiopsie - Negativer Vorhersagewert (Stadieneinteilung)
.... 8.178 Evidence Assessment: Knochenmarkbiopsie - Positiver Vorhersagewert (Stadieneinteilung)
.... 8.179 Evidence Assessment: Knochenmarkbiopsie - Progressionsfreies Überleben
.... 8.180 Evidence Assessment: Knochenmarkbiopsie - Sensitivität (Stadieneinteilung)
.... 8.181 Evidence Assessment: Knochenmarkbiopsie - Spezifität (Stadieneinteilung)
.... 8.182 Evidence Assessment: Knochenmarkbiopsie - Stadieneinteilung
.... 8.183 Evidence-Multiplex PCR Diagnostic-Antibiotic Days
.... 8.184 Evidence-Multiplex PCR Diagnostic-Mortality
.... 8.185 Evidence-Multiplex PCR Diagnostic-Time to Deescalation
.... 8.186 Evidence: Knochenmarkbiopsie - Ereignisfreies Überleben
.... 8.187 Evidence: Knochenmarkbiopsie - Gesamtüberleben
.... 8.188 Evidence: Knochenmarkbiopsie - Negativer Vorhersagewert (Stadieneinteilung)
.... 8.189 Evidence: Knochenmarkbiopsie - Positiver Vorhersagewert (Stadieneinteilung)
.... 8.190 Evidence: Knochenmarkbiopsie - Progressionsfreies Überleben
.... 8.191 Evidence: Knochenmarkbiopsie - Sensitivität (Stadieneinteilung)
.... 8.192 Evidence: Knochenmarkbiopsie - Spezifität (Stadieneinteilung)
.... 8.193 Evidence: Knochenmarkbiopsie - Stadieneinteilung
.... 8.194 Foliensatz
.... 8.195 GfV
.... 8.196 Guideline Attachment Example
.... 8.197 Guideline Attachment Patient Version Example
.... 8.198 Guideline Author Example
.... 8.199 Guideline Author Role Example
.... 8.200 Guideline Example
.... 8.201 Guideline Registry Record Example
.... 8.202 Guideline with contributing author referencing Practitioner (fails invariant)
.... 8.203 Guideline with leading author referencing Organization (passes invariant)
.... 8.204 Guideline with leading author referencing Practitioner (fails invariant)
.... 8.205 HAP Diagnose
.... 8.206 HAP Diagnose - Empfehlung A
.... 8.207 HAP Diagnose - Empfehlung B
.... 8.208 Implementierungshilfe
.... 8.209 Jessica Rademacher
.... 8.210 Jessica Rademacher for DGP in the context of 020-013
.... 8.211 Kurzfassung
.... 8.212 Lale Umutlu
.... 8.213 Lale Umutlu for DRG in the context of 018-038
.... 8.214 Langfassung
.... 8.215 Leitlinienreport
.... 8.216 Medical Society Example
.... 8.217 Multiplex-PCR-Diagnostik
.... 8.218 Netzwerk chronisch pulmonale Aspergillose (CPAnet)
.... 8.219 Outcome Antibiotic Days
.... 8.220 Outcome Mortality
.... 8.221 Outcome Time to Deescalation
.... 8.222 Outcome: Ereignisfreies Überleben
.... 8.223 Outcome: Gesamtüberleben
.... 8.224 Outcome: Negativer Vorhersagewert (Stadieneinteilung)
.... 8.225 Outcome: Positiver Vorhersagewert (Stadieneinteilung)
.... 8.226 Outcome: Progressionsfreies Überleben
.... 8.227 Outcome: Sensitivität (Stadieneinteilung)
.... 8.228 Outcome: Spezifität (Stadieneinteilung)
.... 8.229 Outcome: Stadieneinteilung
.... 8.230 Patienteninformation
.... 8.231 PEG
.... 8.232 PICO Comparator of Recommendation 17 from Guideline 038-013
.... 8.233 PICO Intervention of Recommendation 17 from Guideline 038-013
.... 8.234 PICO Outcome Sensitivity of Recommendation 17 from Guideline 038-013
.... 8.235 PICO Outcome Specificity of Recommendation 17 from Guideline 038-013
.... 8.236 PICO Population of Recommendation 17 from Guideline 038-013
.... 8.237 PICO Question of Recommendation 17 from Guideline 038-013
.... 8.238 Recommendation Example
.... 8.239 Recommendation-PlanDefinition-example
.... 8.240 RecommendationAgainstBoneMarrowBiopsy-Justification
.... 8.241 RecommendationCognitiveTestsWhenSuspectingDementia-Justification
.... 8.242 RecommendationHAPDiagnosis-A-Justification
.... 8.243 RecommendationHAPDiagnosis-B-Justification
.... 8.244 RecommendationMultiplexPCRDiagnostic-Justification
.... 8.245 Robert Koch-Institut
.... 8.246 S3-Leitlinie Demenzen Living Guideline - Langfassung
.... 8.247 S3-Leitlinie Demenzen Living Guideline - Record
.... 8.248 S3-Leitlinie Diagnostik, Therapie und Nachsorge für erwachsene Patient*innen mit einem diffusen großzelligen B-Zell-Lymphom und verwandten Entitäten
.... 8.249 S3-Leitlinie Diagnostik, Therapie und Nachsorge für erwachsene Patient*innen mit einem diffusen großzelligen B-Zell-Lymphom und verwandten Entitäten
.... 8.250 S3-Leitlinie Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie
.... 8.251 S3-Leitlinie Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie
.... 8.252 Screening auf kognitive Beeinträchtigung
.... 8.253 Situationen mit Empfehlungen gegen eine Knochenmarkbiopsie
.... 8.254 Test: Author Both Leading and Contributing (Should Fail)
.... 8.255 Test: No Official Identifier (Should Fail)
.... 8.256 Test: No Official Identifier (Should Fail)
.... 8.257 Test: No Registrant Author (Should Fail)
.... 8.258 Test: Preliminary With Consultation Period (Should Pass)
.... 8.259 Test: Preliminary Without Consultation Period (Should Fail)
.... 8.260 Test: Registered With Planned Completion Date (Should Pass)
.... 8.261 Test: Registered Without Planned Completion Date (Should Fail)
.... 8.262 Test: Release Type If Registered (Should Pass)
.... 8.263 Test: Release Type No Tag (Should Fail)
.... 8.264 Test: Release Type Wrong Code (Should Fail)
.... 8.265 Test: Single Registrant Author (Should Pass)
.... 8.266 Test: Two Official Identifiers (Should Fail)
.... 8.267 Test: Two Official Identifiers (Should Fail)
.... 8.268 Test: Two Registrant Authors (Should Fail)
.... 8.269 Test: Version as Text (Should Fail)
.... 8.270 Test: Version as Text (Should Fail)
.... 8.271 Test: Version Major.Minor.Patch (Should Fail)
.... 8.272 Test: Version Major.Minor.Patch (Should Fail)
.... 8.273 Test: Version with Prefix (Should Fail)
.... 8.274 Test: Version with Prefix (Should Fail)
.... 8.275 Thorsten Persigehl
.... 8.276 Thorsten Persigehl for DRG in the context of 018-038
.... 8.277 Ulrich Dührsen
.... 8.278 Ulrich Dührsen for DGIM in the context of 018-038